Peng H M, Deng H R, Zhou Y W, Wang C F, Lyu J, Mai X D, Yang D Z, Lu J, Xu W, Yan J H
Department of Endocrinology and Metabolic Disease, the Third Affiliated Hospital of Sun Yat-sen University/Guangdong Provincial Key Laboratory of Diabetology, Guangzhou 510630, China.
Department of Endocrinology, the First Affiliated Hospital of the University of Science and Technology of China, HeFei 510945, China.
Zhonghua Yi Xue Za Zhi. 2022 Apr 26;102(16):1190-1195. doi: 10.3760/cma.j.cn112137-20211009-02236.
This study is to investigate the relationship between time in range (TIR) and glucose management indicator (GMI), and the impact of glycemic variability (GV) on their relationship in patients with type 1 diabetes mellitus (T1DM). The CGM data were collected from a multicenter randomized clinical trial of adults (≥18 years old) with T1DM, including 83 T1DM patients, respectively from the Third Affiliated Hospital of Sun Yat-sen University (72 cases), Drum Tower Hospital Affiliated to Nanjing University School of Medicine (2 cases), and the First Affiliated Hospital of University of Science and Technology of China (9 cases). All subjects wore the iPro2 system for 14 days at baseline (0-2 weeks), 3 months (12-14 weeks), and 6 months (24-26 weeks). Data derived from iPro2 sensor was used to calculate CGM parameters. Correlation between TIR and GMI was explored according to different stratification of glycemic variability assessed by glucose coefficient of variation (). Predicted TIR in the fixed GMI value was calculated via the linear regression equations performed in the respective interquartile group of . From November 2017 to June 2021, a total of 233 CGM data were collected with 83 collected from baseline, 80 from the 3-month follow-up, 70 from the 6-month follow-up. Patients including 27 males had a median (, ) age of 30.69 (25.22, 38.43) years, with a diabetes duration of 10.05(4.46, 13.92) years. The median (, ) and effective wearing time of available CGM data was 13.92 (13.02, 14.00) days and 91.61% (84.96%, 95.94%), and the value of TIR, GMI and was 60.34%±13.03%, 7.14%±0.61% and 41.01%±7.64%, respectively. There was a strong negative correlation between TIR and GMI (=-0.822, <0.001). Multiple linear regression analysis showed that the predictive value of TIR calculated from a given GMI was 8.352% higher when was up to standard (36%) than that when was down to standard. Based on the multiple linear regression equations generated from quartiles of , the predicted TIR value was decreased across the ascending quartiles with 69.98 % in the lowest quartile of (≤35.91%), 64.57 % in 25-50 quartile of (35.91%<≤40.08%), 60.96% in 50-75 quartile of (40.08%<≤45.86%) and 56.44% in the highest quartile of (>75 quartile, >45.86%) when GMI was set as 7%. There is a strong correlation between TIR and GMI in adult patients with T1DM in patients with type 1 diabetes mellitus. influenced the relationship between TIR and GMI.
本研究旨在探讨1型糖尿病(T1DM)患者的血糖达标时间(TIR)与血糖管理指标(GMI)之间的关系,以及血糖变异性(GV)对二者关系的影响。连续血糖监测(CGM)数据来自一项针对成年(≥18岁)T1DM患者的多中心随机临床试验,共纳入83例T1DM患者,分别来自中山大学附属第三医院(72例)、南京大学医学院附属鼓楼医院(2例)和中国科学技术大学附属第一医院(9例)。所有受试者在基线期(0 - 2周)、3个月(12 - 14周)和6个月(24 - 26周)佩戴iPro2系统14天。利用iPro2传感器获取的数据计算CGM参数。根据血糖变异系数( )评估的血糖变异性不同分层,探究TIR与GMI之间的相关性。通过在 的各四分位数组中进行线性回归方程,计算固定GMI值下的预测TIR。2017年11月至2021年6月,共收集233份CGM数据,其中基线期83份、3个月随访期80份、6个月随访期70份。患者中男性27例,年龄中位数( , )为30.69(25.22,38.43)岁,糖尿病病程为10.05(4.46,13.92)年。有效CGM数据的中位数( , )及佩戴时间分别为13.92(13.02,14.00)天和91.61%(84.96%,95.94%),TIR、GMI和 的值分别为60.34%±13.03%、7.14%±0.61%和41.01%±7.64%。TIR与GMI之间存在强负相关( = - 0.822, <0.001)。多元线性回归分析显示,当 达标(36%)时,由给定GMI计算出的TIR预测值比 未达标时高8.352%。根据 的四分位数生成的多元线性回归方程,当GMI设定为7%时,随着 的四分位数升高,预测TIR值降低,在 的最低四分位数(≤35.91%)为69.98%,在 的25 - 50四分位数(35.91%< ≤40.08%)为64.57%,在 的50 - 75四分位数(40.08%< ≤45.86%)为60.96%,在 的最高四分位数(>75四分位数,>45.86%)为56.44%。1型糖尿病成年患者中,TIR与GMI之间存在强相关性。 影响TIR与GMI之间的关系。